Pretransplant Induction Regimens for Multiple Myeloma

被引：1
作者：
Vesole, David H. [1 ]
Siegel, David S. [1 ]
机构：
[1] Hackensack UMC, Hackensack, NJ 07601 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 02期
关键词：
STEM-CELL TRANSPLANTATION; DISEASE; SINGLE;
D O I：
10.1016/j.bbmt.2014.12.013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：200 / 201
页数：2
相关论文
共 50 条
  • [21] Management of multiple myeloma in younger patients
    Strifler, S.
    Einsele, H.
    ONKOLOGE, 2018, 24 (08): : 604 - 608
  • [22] New developments in conditioning regimens before auto-SCT in multiple myeloma
    Moreau, P.
    Attal, M.
    Harousseau, J. L.
    BONE MARROW TRANSPLANTATION, 2011, 46 (07) : 911 - 915
  • [23] Multiple Myeloma-Effect of Induction Therapy on Transplant Outcomes
    Kumar, Lalit
    Gundu, Naresh
    Kancharia, Harish
    Sahoo, Ranjit Kumar
    Malik, Prabhat Singh
    Sharma, Atul
    Gupta, Ritu
    Sharma, Omdutt
    Biswas, Ahitagni
    Kumar, Rakesh
    Thulkar, Sanjay
    Mallick, Saumyaranjan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (02) : 80 - +
  • [24] Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation
    Shah, Gunjan L.
    Landau, Heather
    Londono, Dory
    Devlin, Sean M.
    Kosuri, Satyajit
    Lesokhin, Alexander M.
    Lendvai, Nikoletta
    Hassoun, Hani
    Chung, David J.
    Koehne, Guenther
    Jhanwar, Suresh C.
    Landgren, Ola
    Levine, Ross
    Giralt, Sergio A.
    LEUKEMIA & LYMPHOMA, 2017, 58 (08) : 1823 - 1831
  • [25] Imaging of Multiple Myeloma
    Amos, Barry
    Agarwal, Amit
    Kanekar, Sangam
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (04) : 843 - +
  • [26] Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma
    Moreau, Philippe
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) : 885 - 890
  • [27] Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma
    Banerjee, Rahul
    Williams, Louis
    Mikhael, Joseph R.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [28] The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
    Ho, Matthew
    Zanwar, Saurabh
    Kapoor, Prashant
    Gertz, Morie
    Lacy, Martha
    Dispenzieri, Angela
    Hayman, Suzanne
    Dingli, David
    Baudi, Francis
    Muchtar, Eli
    Leung, Nelson
    Kourelis, Taxiarchis
    Warsame, Rahma
    Fonder, Amie
    Hwa, Lisa
    Hobbs, Miriam
    Kyle, Robert
    Rajkumar, S. Vincent
    Kumar, Shaji
    BLOOD CANCER JOURNAL, 2021, 11 (09)
  • [29] Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma
    Zou, Yandun
    Sheng, Zhixin
    Niu, Shaona
    Wang, Huijuan
    Yu, Jinming
    Xu, Jingbo
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2219 - 2225
  • [30] Retrospective Comparison of Bortezomib-containing Regimens with Vincristine-Doxorubicin-Dexamethasone (VAD) as Induction Treatment Prior to Autologous Stem Cell Transplantation for Multiple Myeloma
    Eom, Hyeon-Seok
    Min, Chang-Ki
    Cho, Byung-Sik
    Lee, Seok
    Lee, Jong-Wook
    Min, Woo-Sung
    Kim, Chun-Choo
    Kim, Myungshin
    Kim, Yonggoo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (07) : 449 - 455
12345